Candel Therapeutics annual capital expenditures (capex)
2020
2021
2022
2023
2024
2025
Candel Therapeutics Capital Expenditures (CapEx) Growth & History (CADL)
Candel Therapeutics's capital expenditures (capex) was $587,000 for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $587,000 | $571,000 | +3568.75% |
| 2024 | 2024-12-31 | $16,000 | −$441,000 | −96.50% |
| 2023 | 2023-12-31 | $457,000 | −$840,000 | −64.76% |
| 2022 | 2022-12-31 | $1.3M | −$538,000 | −29.32% |
| 2021 | 2021-12-31 | $1.8M | $359,000 | +24.32% |
| 2020 | 2020-12-31 | $1.5M | — | — |
Candel Therapeutics quarterly capital expenditures (capex)
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $69,000 | $38,000 | +122.58% |
| Q1 2026 | 2026-03-31 | $675,000 | $672,000 | +22400.00% |
| Q4 2025 | 2025-12-31 | $409,000 | $406,000 | +13533.33% |
| Q3 2025 | 2025-09-30 | $144,000 | $144,000 | — |
| Q2 2025 | 2025-06-30 | $31,000 | $25,000 | +416.67% |
| Q1 2025 | 2025-03-31 | $3,000 | −$4,000 | −57.14% |
| Q4 2024 | 2024-12-31 | $3,000 | −$44,000 | −93.62% |
| Q3 2024 | 2024-09-30 | $0 | −$103,000 | — |
| Q2 2024 | 2024-06-30 | $6,000 | −$163,000 | −96.45% |
| Q1 2024 | 2024-03-31 | $7,000 | −$131,000 | −94.93% |
| Q4 2023 | 2023-12-31 | $47,000 | −$229,000 | −82.97% |
| Q3 2023 | 2023-09-30 | $103,000 | −$112,000 | −52.09% |
| Q2 2023 | 2023-06-30 | $169,000 | −$466,000 | −73.39% |
| Q1 2023 | 2023-03-31 | $138,000 | −$33,000 | −19.30% |
| Q4 2022 | 2022-12-31 | $276,000 | −$228,000 | −45.24% |
| Q3 2022 | 2022-09-30 | $215,000 | −$177,000 | −45.15% |
| Q2 2022 | 2022-06-30 | $635,000 | −$75,000 | −10.56% |
| Q1 2022 | 2022-03-31 | $171,000 | −$58,000 | −25.33% |
| Q4 2021 | 2021-12-31 | $504,000 | — | — |
| Q3 2021 | 2021-09-30 | $392,000 | −$334,000 | −46.01% |
| Q2 2021 | 2021-06-30 | $710,000 | — | — |
| Q1 2021 | 2021-03-31 | $229,000 | — | — |
| Q3 2020 | 2020-09-30 | $726,000 | — | — |
Candel Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Candel Therapeutics's capital expenditures (capex) decreased from $1.5M to $587,000, a change of −$889,000. The latest reported quarter, Q2 2026, shows $69,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗